HC Wainwright has started coverage of Oncomed Pharmaceuticals Inc (NASDAQ: OMED) shares with a Buy rating. The firm sees 68 percent potential upside for the
pharmaceutical company on upcoming opt-in decisions for its lead drug candidates expected from three partners: Celgene
Corporation (NASDAQ: CELG), Bayer AG
(ADR) (OTC: BAYRY) and GlaxoSmithKline plc
(ADR) (NYSE: GSK).
The brokerage expects OncoMed to share in demcizumab's potential success with Celgene, while OncoMed's co-promotion rights give
the company greatest exposure to Celgene partnership.
Redwood City-based OncoMed's lead anti-DLL4 monoclonal antibody demcizumab is actively being evaluated in combination regimens
for pancreatic and non-small cell lung cancer (NSCLC).
"We believe a positive readout from the Phase 2 YOSEMITE trial in pancreatic cancer could lead partner Celgene to opt-in to the
demcizumab program in early 2017, followed by readout from the Phase 2 DENALI trial in NSCLC a year later," analyst Shaunak Deepak
wrote in a note.
Related Link: Shkreli
Warned You: Mast Therapeutics Plummets 80% After Sickle Cell Drug Phase 3 Trial Fail
Meanwhile, the upcoming data of vantictumab in breast cancer patients could drive Bayer's opt-in to the Wnt program in 2017.
"We regard the pancreatic cancer indication as a source of potential upside for our vantictumab estimates. We see the second Wnt
pathway antagonist ipafricept as a source of potential upside," Deepak highlighted.
Further, the analyst expects GlaxoSmithKline may opt-in to develop tarextumab, as it may show activity in lung cancer despite
the compound failed in pancreatic cancer trial.
"In addition to near-term opt-in milestones that could reach $172 million, we believe these partnerships could payoff with
long-term benefits and free-up OncoMed's resources to pursue new development activities," Deepak added.
Deepak's $20 price target assumes $10 for demcizumab, $4 for vantictumab, $2 for tarextumab and $4 for YE16 cash of $171.50
million.
Shares of OncoMed closed Wednesday's trading at $11.87. At time of publication Thursday, OncoMed was up 1.94 percent at
$12.10.
Full ratings
data available on Benzinga Pro.
Do you have ideas for articles/interviews you'd like to see more of on Benzinga? Please email feedback@benzinga.com with your best article ideas. One person will be randomly selected to win
a $20 Amazon gift card!
Latest Ratings for OMED
Date |
Firm |
Action |
From |
To |
Sep 2016 |
H.C. Wainwright |
Initiates Coverage on |
|
Buy |
Aug 2016 |
Jefferies |
Maintains |
|
Buy |
May 2016 |
Leerink Swann |
Maintains |
|
Market Perform |
View More Analyst Ratings for
OMED
View the Latest Analyst Ratings
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.